{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Niu L"],"funding":["Medical Science and Technology Foundation of Guangdong Province","National Key R&D Program of China","Pearl River Talent Recruitment Program","Basic and Applied Basic Research Foundation of Guangdong Province","National Natural Science Foundation of China"],"pagination":["e15712"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12499428"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(37)"],"pubmed_abstract":["Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune dysregulation and impaired Treg cell differentiation. Mesenchymal stem cell-derived exosomes (MSC-exos) hold promise for treating immune-related diseases, while their clinical application is hindered by the limited production and non-specific organ distribution. In this study, a combined engineering strategy is developed for MSC-exo via aggregation culture and genetic editing, achieving a substantial increase in both exosome yield and therapeutic specificity in SLE. First, MSCs produce a high yield of engineered exosomes through an aggregation culture engineering strategy (Agg-exo), demonstrating immune organ targeting and promoting Tregs via the Foxp1/STAT5/Foxp3 axis. Then, MSCs are engineered by overexpressing Foxp1 in order to acquire Foxp1<sup>high</sup> Agg-exo with enhanced immunomodulatory properties, which showes superior therapeutic effect for SLE. Taken together, a newly dual-engineering strategy is developed to produce high-yield, Foxp1<sup>high</sup> Agg-exo, which solved the limitation of low-yield production and non-specific organ distribution of MSC-exos. This innovative strategy holds great potential for the development of exosome-based therapies in autoimmune diseases."],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Engineered Foxp1&lt;sup&gt;high&lt;/sup&gt; Exosomes Ameliorates Systemic Lupus Erythematosus."],"pmcid":["PMC12499428"],"funding_grant_id":["A2024558","82401065","2019JC01Y182","2019ZT08Y485","82371005","2023A1515111124","2021YFA1100600"],"pubmed_authors":["Ou Q","Li Z","Shi S","Chen Z","Lei F","Teng W","Mao X","Niu L","Chen H","Ren Q"],"additional_accession":[]},"is_claimable":false,"name":"Engineered Foxp1&lt;sup&gt;high&lt;/sup&gt; Exosomes Ameliorates Systemic Lupus Erythematosus.","description":"Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune dysregulation and impaired Treg cell differentiation. Mesenchymal stem cell-derived exosomes (MSC-exos) hold promise for treating immune-related diseases, while their clinical application is hindered by the limited production and non-specific organ distribution. In this study, a combined engineering strategy is developed for MSC-exo via aggregation culture and genetic editing, achieving a substantial increase in both exosome yield and therapeutic specificity in SLE. First, MSCs produce a high yield of engineered exosomes through an aggregation culture engineering strategy (Agg-exo), demonstrating immune organ targeting and promoting Tregs via the Foxp1/STAT5/Foxp3 axis. Then, MSCs are engineered by overexpressing Foxp1 in order to acquire Foxp1<sup>high</sup> Agg-exo with enhanced immunomodulatory properties, which showes superior therapeutic effect for SLE. Taken together, a newly dual-engineering strategy is developed to produce high-yield, Foxp1<sup>high</sup> Agg-exo, which solved the limitation of low-yield production and non-specific organ distribution of MSC-exos. This innovative strategy holds great potential for the development of exosome-based therapies in autoimmune diseases.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-04T04:50:07.215Z","creation":"2026-05-05T03:12:44.079Z"},"accession":"S-EPMC12499428","cross_references":{"pubmed":["40605719"],"doi":["10.1002/advs.202415712"]}}